Better control, efficiency with upgraded phaco system
November 1st 2006The Sovereign WhiteStar ICE (Increased Control and Efficiency) system (Advanced Medical Optics [AMO]), with its ultrasound pulse-shaping technology, is proving to be more efficient in recent clinical studies. The results of two studies reported at the American Society of Cataract and Refractive Surgery annual meeting added to that body of information.
Self-assessed visual results found similar with blue-light-blocking and aspheric IOLs
November 1st 2006Garden City, KS-Cataract surgery patients do not notice a significant difference in vision between two lenses-the blue-light-blocking spherical SN60AT IOL (AcrySof Natural, Alcon Laboratories) and the aspheric SN60WF IOL (AcrySof IQ, Alcon Laboratories)-according to the results of a small, randomized, fellow eye controlled study. Luther L. Fry, MD, a private practitioner in Garden City, KS, reported the results.
Preop patient counseling, choice of lens key for those who desire spectacle independence
November 1st 2006Bellville, Cape Town, South Africa-The Tecnis multifocal lens (Advanced Medical Optics) is effective and safe and provides excellent distance and near visual outcomes. Preoperative patient counseling is imperative as well as careful biometry, meticulous reproducible surgery, and astigmatic neutral surgery, all of which are keys to the success of the procedure, according to Johann Kruger, FRCS.
Sealed capsule irrigation device helps prevent PCO development in small eyes
November 1st 2006Stockholm, Sweden-The Perfect Capsule (Milvella), a sealed capsule irrigation device, seems to be very useful in very small eyes for preventing posterior capsular opacification (PCO), according to Maria Kugelberg, MD, PhD.
Capsular dyes make the extraordinary ordinary
November 1st 2006Since the advent of cataract extraction with phacoemulsification, modern cataract surgery has evolved in small incremental steps that have ultimately transformed our technique into its current advanced state. The introduction of foldable IOLs, continuous curvilinear capsulorhexis, topical anesthesia, clear corneal incisions, power modulations, iris hooks, and capsular tension rings are just a handful of the valuable innovations that have made cataract surgery safe and efficacious. I believe that one of the simplest and most indispensable advances to be made in the last several decades has been the introduction of capsular dyes.
Early cataract extraction at 60 years or older is justified
November 1st 2006Fukuoka, Japan-Extraction of cataracts that develop early in patients who are 60 years of age or older may be justified when the results of a recent study of accommodation are considered. The investigators found that the amplitude of apparent accommodation is almost the same as that of normal accommodation in these patients, according to Ken Hayashi, MD.
Variable dosing of ranibizumab investigated for treatment of neovascular AMD
November 1st 2006Miami-One year into a 2-year study using an optical coherence tomography (OCT)-guided variable dosing regimen for ranibizumab (Lucentis, Genentech) for neovascular age-related macular degeneration (AMD), two key findings have emerged, according to lead investigator Philip Rosenfeld, MD, PhD.
Early benefits of epi-LASIK seen with flap replacement
November 1st 2006New York-Patients undergoing surface ablation procedures performed using the Epi-K (Moria) for epithelial flap creation had better uncorrected visual acuity (UCVA) and comfort early on when the flap was replaced (epi-LASIK) than when it was removed (advanced surface treatment). However, surface ablation with flap removal may be associated with a benefit of better UCVA at 1 month, according to the results of a prospective clinical trial.
Risk of significant postoperative cylinder examined
November 1st 2006Rochester, NY-The incidence of postoperative astigmatism is significantly associated with the presence of preoperative coma, secondary astigmatism, and the discrepancy in preoperative astigmatism between wavefront and manifest subjective refractions, according to Manoj Subbaram, PhD.
Foldable phakic IOL corrects myopia
November 1st 2006Maastricht, The Netherlands-Preliminary results with the foldable iris-claw myopic phakic IOL (Artiflex, Ophtec) indicate it has a similar safety index when compared with the original polymethylmethacrylate (PMMA) model (Artisan, Ophtec), but is associated with less early induced refractive astigmatism, which results in a better efficacy index initially and shorter visual recovery curve, said Rudy M.M.A. Nuijts, MD, PhD.
Wavefront-guided LASIK appropriate for patients with mixed astigmatism
November 1st 2006Margate, FL-Eyes with mixed astigmatism have a range of naturally occurring higher-order aberrations that consist primarily of coma and spherical aberration. Wavefront-guided LASIK may be beneficial over conventional LASIK because of decreased higher-order aberrations overall, according to Raymond Gailitis, MD.
Wavefront-guided LASIK helpful tool for residual myopia
November 1st 2006Stanford, CA-Wavefront-guided LASIK re-treatment procedures with the VISX CustomVue platform (VISX/Advanced Medical Optics [AMO]) seem to be effective, predictable, and safe in eyes with residual myopia using Fourier-based treatment software, reported Gloria Wang, MD.
Conventional LASIK, epi-LASIK, lamellar epithelial debridement possible with same tool
November 1st 2006New York-The latest upgrades to the Amadeus II microkeratome (Advanced Medical Optics) offer surgeons the flexibility to perform epi-LASIK and lamellar epithelial debridement as well as conventional LASIK without adding a new handpiece or control box. The only new components required are a small holder for the separator used in epi-LASIK as well as a new head, both of which are part of the package when the Amadeus II is purchased, according to Eric Donnenfeld, MD, FAAO, FACS, Ophthalmic Consultants of Long Island.
Fourier-based refractive treatment advantageous in myopic patients
November 1st 2006Stanford, CA-Myopic patients who underwent CustomVue wavefront LASIK with the S4 laser (VISX, Advanced Medical Optics) with a Fourier-based program had better efficacy and predictability 1 year after the surgery than those with a Zernike-based system, according to Judy I. Ou, MD.
Good functional vision in presbyopic patients is attainable
November 1st 2006Since our practice began offering presbyopia-correcting IOLs, we have implanted 450 of them. One in five of our cataract and refractive lens exchange patients chooses one of these new lenses. The AcrySof ReSTOR lens (Alcon Laboratories) accounts for 80% of our presbyopia-correcting implants, while the ReZoom (Advanced Medical Optics) and the crystalens (eyeonics) together represent 20%.
Presbyopia treatments yielding positive results
November 1st 2006Bogota, Colombia-Results from lengthening follow-up of patients who have undergone CustomVue (Advanced Medical Optics/VISX) peripheral excimer laser ablation indicate it is a safe and effective treatment for myopia and pure presbyopia. Also, initial results are encouraging regarding the benefit of iris registration for enhancing outcomes of wavefront-guided multifocal ablation to treat hyperopic presbyopia, said Gustavo E. Tamayo, MD.
Surface ablation procedures differ in terms of visual recovery, comfort
November 1st 2006New York-Several options can be offered to refractive surgery patients who are candidates for surface ablation procedures, and those individuals should be informed about differences between procedures with respect to speed of visual rehabilitation and postoperative comfort, said Gary R. Fishman, MD.
Dr. Hnik joins iCo Therapeutics as CMO
November 1st 2006Vancouver, British Columbia-Peter Hnik, MD, MHS, has been named chief medical officer of iCo Therapeutics Inc. The biotechnology company is developing pre-existing drugs for a range of new conditions affecting isolated biologic environments-areas such as the eye, spinal cord, and joints, where locally administered application of these therapies would have minimal systemic distribution and fewer safety issues.
Ophthalmology Times: 30 years old but still funky
November 1st 2006In November 1976, President Gerald Ford and Vice-President Nelson Rockefeller likely "got down" to the popular new song, "Play That Funky Music" and viewed the top-grossing movie, Rocky. Mao Tse-Tung died, two amateur electronics enthusiasts developed the Apple computer in a California garage, USC beat Michigan in the Rose Bowl, the Celtics swept Phoenix in the NBA finals, and Cincinnati prevailed over the Yankees in the World Series. The cost of a home averaged $48,000, a gallon of gas was 59 cents, the Dow's high for the year was 1,004, yours truly was a college sophomore, and Ophthalmology Times mailed its first issue.
Italian group probes refractive surgery patient opinions
November 1st 2006Bescia, Italy-A patient questionnaire about their experience with refractive surgery is in the process of development by the Italian Refractive Surgery Society. The preliminary results reported by Elena Scaffidi, Psych MA, indicate that the questionnaire was well perceived by patients and provided a great deal of input for improving their experience.
Complement molecules may lead to early AMD detection
November 1st 2006Lexington, KY-Animal studies point to two components of drusen as the driving force for the neovascularization that causes age-related macular degeneration (AMD) -a discovery that opens the way to early detection and drug therapy to prevent the condition, said Jayakrishna Ambati, MD.
OXiGENE tests CA4P for macular disease
November 1st 2006Waltham, MA-OxiGENE Inc., a clinical-stage biopharmaceutical company developing novel therapies to treat eye diseases and cancer, is now focusing its ophthalmology strategy on oral or other non-intravitreal forms of administration of Combretastatin A4 Phosphate (CA4P) for age-related macular degeneration.
Phase II trial tests mifepristone
November 1st 2006Boston-Global bio-nanotech company pSivida Ltd. has begun a phase II clinical trial of the steroid receptor antagonist mifepristone (RU486) as an eye-drop treatment for steroid-associated elevated IOP. The investigator-sponsored trial is expected to involve up to 45 patients in the United States.